Investing.comCodex · 实盘不做把握 2/10
北京时间·🕒 发布 04:04:47时区推断·⟳ 抓取 04:05:38·⚡ 决策 07-28 04:06:48 +1m10s·91.9 天前
ProMIS将举办阿尔茨海默病1b期试验中期数据网络研讨会
当前信号只是公司宣布将在次日讨论PRECISE-AD 1b期六个月盲态汇总安全性和部分生物标志物趋势，尚未披露明确疗效、安全性或监管结果。
📄 原文Investing.com↗ 原文
ProMIS to host webinar on Alzheimer’s trial interim data
Oil prices tumble after U.S. and Iran pause fighting, Brent falls below $90 CAMBRIDGE, Mass. - ProMIS Neurosciences Inc…
不做 ProMIS Neurosciences（PMN.US）
仅为临床试验中期数据研讨会预告，尚无明确疗效、安全性或监管新增事实，方向无法判断；等实际数据披露后由新信号重新研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 low · price-in 风险 medium ↗
关键理由
- 当前信号只是公司宣布将在次日讨论PRECISE-AD 1b期六个月盲态汇总安全性和部分生物标志物趋势，尚未披露明确疗效、安全性或监管结果。
主要风险
- 真正可交易的信息要等研讨会实际披露数据后再判断，提前交易属于赌数据。
原文全文
展开原文 · 1,857 字
Oil prices tumble after U.S. and Iran pause fighting, Brent falls below $90
CAMBRIDGE, Mass. - ProMIS Neurosciences Inc. (NASDAQ:PMN) announced it will host a webinar on Tuesday at 8:00 a.m. ET to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial, according to a press release statement.
The webinar will feature Dr. Will Mantyh, Associate Professor at University of Minnesota Medical School, and Dr. Michael Weiner, Professor Emeritus at University of California, San Francisco, alongside company leadership. The discussion will focus on blinded aggregate safety data and trends in select biomarkers from the trial evaluating PMN310 in patients with early Alzheimer’s disease.
PMN310 is a humanized IgG1 monoclonal antibody designed to target toxic oligomers of amyloid-beta while avoiding binding to amyloid plaques and vascular deposits. The company states this selectivity may reduce the risk of amyloid-related imaging abnormalities, including brain swelling and microhemorrhages.
The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses of intravenous PMN310. The study has completed enrollment of 144 participants across three dosing cohorts who are being treated for twelve months.
PMN310 received Fast Track Designation from the U.S. Food and Drug Administration in July 2025. The company initiated the Phase 1b trial based on results from a Phase 1a trial in healthy volunteers.
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases. The company has offices in Cambridge, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - ProMIS Neurosciences Inc. (NASDAQ:PMN) announced it will host a webinar on Tuesday at 8:00 a.m. ET to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial, according to a press release statement.
The webinar will feature Dr. Will Mantyh, Associate Professor at University of Minnesota Medical School, and Dr. Michael Weiner, Professor Emeritus at University of California, San Francisco, alongside company leadership. The discussion will focus on blinded aggregate safety data and trends in select biomarkers from the trial evaluating PMN310 in patients with early Alzheimer’s disease.
PMN310 is a humanized IgG1 monoclonal antibody designed to target toxic oligomers of amyloid-beta while avoiding binding to amyloid plaques and vascular deposits. The company states this selectivity may reduce the risk of amyloid-related imaging abnormalities, including brain swelling and microhemorrhages.
The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses of intravenous PMN310. The study has completed enrollment of 144 participants across three dosing cohorts who are being treated for twelve months.
PMN310 received Fast Track Designation from the U.S. Food and Drug Administration in July 2025. The company initiated the Phase 1b trial based on results from a Phase 1a trial in healthy volunteers.
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases. The company has offices in Cambridge, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。